Skip to main content

ALUMIS INC.

corporate_fare Company Profile

ALUMIS INC.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ALMS - Latest Insights

ALMS
Mar 30, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 5:02 PM EDT
Filing Type: S-3ASR
Importance Score:
7
ALMS
Mar 19, 2026, 4:23 PM EDT
Filing Type: 10-K
Importance Score:
8
ALMS
Mar 19, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
ALMS
Jan 13, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
7
ALMS
Jan 13, 2026, 6:18 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ALMS
Jan 12, 2026, 9:59 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ALMS
Jan 09, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
8
ALMS
Jan 08, 2026, 5:29 PM EST
Filing Type: 424B5
Importance Score:
8
ALMS
Jan 06, 2026, 5:24 PM EST
Filing Type: 424B5
Importance Score:
8
ALMS
Jan 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
ALMS
Jan 06, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
9